Pharvaris N.V.
deucrictibant IR
HAE attacks
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on deucrictibant IR for HAE attacks is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“Submission of New Drug Application (NDA) of deucrictibant immediate release (IR) capsule for the on-demand treatment of HAE attacks remains on-track for 1H2026.”